B7-H4在人胶质瘤组织中的表达及其临床意义

 目的： 探讨B7-H4在人胶质瘤组织中的表达及其临床意义。方法： HE染色分析了150例胶质瘤标本病理级别。免疫组化方法检测B7-H4在胶质瘤中的表达, 并分析其与临床病理参数及生存时间的关系。结果： HE染色检测150例胶质瘤标本病理级别，结果为I级12 例，II级50 例，III级39 例，IV级49 例。150例胶质瘤标本中97例B7-H4高表达，高表达率为64.7％，居于病理级别III～IV级；43例B7-H4低表达，低表达率为28.7%，居于病理级别I～II级。统计学分析提示组织标本中B7-H4的表达与年龄(P<0.01)和病理级别(P<0.01)存在明显相关，与肿瘤的部位没有显著相关性（P>0.05）。B7-H4阳性患者生存期更短（P<0.01），多因素Cox 回归分析显示B7-H4、年龄、性别及病理级别均是胶质瘤患者的独立预后因素。结论： B7-H4在多数胶质瘤组织中表达较高，可作为脑胶质瘤患者的独立预后分子标志物和新的治疗靶点。

Expression of B7-H4 in human glioma tissues and its clinical significance

AIM: To investigate the expression of B7-H4 in human glioma tissues and its clinical significance. METHODS: The histological staging of 150 cases of human glioma tissues was determined by HE staining. Immunohistochemistry was performed to study the protein level of B7-H4 in 150 human glioma specimens. Furthermore, the relationships between the expression level of B7-H4 and clinicopathological parameters, as well as patients survival rate, were analyzed. RESULTS: HE staining result indicated that there were 12 cases staged as stage I, 50 cases stage II, 39 cases stage III and 49 cases stage IV in 150 glioma specimens. Ninety-seven cases highly expressed B7-H4 in total 150 glioma samples with a 64.7% high expression rate. The histological grade of the tissues with high B7-H4 expression was mostly III~IV. There were 53 cases with low B7-H4 expression in the total 150 glioma patients with a 35.3% low expression rate. The histological grade of the tissues with low B7-H4 expression was mostly I~II. The B7-H4 expression was related to the age of the patients (P<0.01) and the pathological grade of glioma (P<0.01), but not related to the location of glioma (P>0.05). Kaplan-Meier survival curves demonstrated that increased B7-H4 expression was associated with shorter overall survival time (P<0.01). Multivariate Cox regression analysis revealed that B7-H4, age, sex and pathological grade were independent prognostic factors in glioma patients. CONCLUSION: B7-H4 is expressed in most of glioma tissues. B7-H4 may be a novel prognostic biomarker and a new target of molecular therapy for gliomas.